Company profile
SUTRO BIOPHARMA, INC.
NASDAQ:STROBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Bezetabart Debotansine | phase1 | — | 1 | no active trials |
| Luveltamab Tazevibulin | phase1 | — | 2 | completed, terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05200364 | phase1 | terminated | 2022-03-22 | 2025-06-01 | Sutro Biopharma, Inc. | A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer |
| NCT07227168 | phase1 | recruiting | 2025-11-07 | 2027-12-01 | Sutro Biopharma, Inc. | A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer |
| NCT06679582 | phase1_2 | terminated | 2024-12-04 | 2025-06-01 | Sutro Biopharma, Inc. | Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML |
| NCT05870748 | phase2_3 | terminated | 2023-07-12 | 2025-08-26 | Sutro Biopharma, Inc. | REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 |
| NCT03424603 | phase1 | completed | 2018-02-22 | 2024-02-15 | Sutro Biopharma, Inc. | Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies |
FDA applications (0)
No records yet.